Related Experiment Videos
Granulocyte colony stimulating factor (G-CSF) for mustard-induced bone marrow suppression
B R Meisenberg1, A J Melaragno, R L Monroy
1Department of Internal Medicine (Hematology/Oncology Division), Naval Hospital, San Diego, CA 92134-5000.
Military Medicine
|July 1, 1993
Summary
This study details a clinical protocol using granulocyte colony-stimulating factor (G-CSF) to treat myelosuppression caused by mustard gas exposure. G-CSF shows promise in mitigating neutropenia and improving outcomes for victims.
Area of Science:
- Toxicology
- Hematology
- Clinical Medicine
Background:
- Mustard gas exposure can lead to myelosuppression, a significant factor in victim morbidity.
- Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor with potential therapeutic applications.
- Limited clinical evidence exists for treating mustard gas-induced myelosuppression.
Purpose of the Study:
- To develop a clinical protocol for treating mustard gas-induced myelosuppression using G-CSF.
- To leverage existing knowledge of G-CSF safety and efficacy from oncologic applications.
Main Methods:
- Review of clinical evidence regarding mustard gas toxicity.
- Analysis of preclinical data in primates showing G-CSF's effect on neutropenia after nitrogen mustard exposure.
- Adaptation of established G-CSF protocols from cancer treatment.
Main Results:
- G-CSF demonstrated the ability to ameliorate neutropenia in primate models following nitrogen mustard exposure.
- Extensive oncologic data confirm the safety and tolerability of G-CSF.
- A clinical protocol was developed for potential use in mustard gas victims.
Conclusions:
- G-CSF presents a viable therapeutic option for managing mustard gas-induced myelosuppression.
- The developed protocol aims to improve the clinical management of mustard gas casualties.
- Further clinical investigation is warranted to validate G-CSF efficacy in human victims.